Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

BioVie Inc

BIVI ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.40

▼ -10.26%

Market Cap $10.56M · Vol 296.89K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.56M

Micro Cap

Div Yield

N/A

EPS Growth

+79.34%

YoY

RSI (14)

50.57

Momentum

Beta

0.65

vs Market

52W High

$3.79

63.06% below

52W Low

$0.82

70.71% above

Volume

296.89K

Avg 517.08K

P/B

1.42

Price-to-book

ROE

N/A

Return on equity

Free Float

99.70%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, BioVie Inc (BIVI) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does BIVI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+40.10%

-11.39%

+1.45%

+10.24%

YTD

+20.69%

-15.66%

-99.65%

-99.83%

Financials & Valuation

TTM · Annual

Total Revenue	N/A
Net Income	N/A
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	N/A · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.42
P/FCF	N/A
EPS Growth	+79.34%
Outstanding Shares	7.54M

Technical Indicators

50-Day SMA	$1.68
200-Day SMA	$1.47
RSI (14)	50.57
Beta	0.65
52-Week High	$3.79
52-Week Low	$0.82

Volume Today	296.89K
Avg Daily Volume (30D)	517.08K
Relative Volume	0.57x
Volatility (10D)	306.12
Volatility (30D)	223.45
Free Float	99.70%

Analyst Consensus

BUY

Current Price $1.40

Mean Target $5.26

52W Low$0.82 52W High$3.79

Current

Target

$0.82 $3.79

Current Analyst target

+275.36% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00548BTF4

ISINUS09074F5044

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 11, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.